This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
BPC-157 + TB-500 (10 mg Blend)
This information is for research and educational use only.
Quick Reference
What is BPC-157 + TB-500?
Research overview based on the cited scientific literature.
• Goal: Support tissue repair, wound healing, and recovery from musculoskeletal injuries[1][3].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality and stability.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4–6 weeks; avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is BPC-157 + TB-500 studied?
BPC-157 is a stable pentadecapeptide that promotes angiogenesis, modulates nitric oxide pathways, and demonstrates broad cytoprotective effects across gastrointestinal, musculoskeletal, and neurological tissues in preclinical models[1][2]. It has shown activity at very low doses (nanogram to microgram per kilogram) without demonstrable toxicity in animal studies[11].
TB-500 (Thymosin Beta-4) is an actin-sequestering peptide that promotes cell migration, wound healing, and anti-inflammatory responses[3][4]. It is well-tolerated in animal and early clinical studies, even at multi-milligram doses[12].
Combining these peptides may provide complementary mechanisms for tissue repair: BPC-157 for its trophic and anti-inflammatory effects, and TB-500 for enhanced cell migration and angiogenesis[8].
What does the research report about BPC-157 + TB-500?
Observations from preclinical and limited clinical literature.
• May support accelerated healing of tendons, ligaments, muscles, and soft tissue injuries[1][5].
• Preclinical evidence suggests gastroprotective and anti-inflammatory properties for BPC-157[2].
• TB-500 promotes wound healing and may reduce scarring through enhanced cell migration[3].
• Both peptides are generally well tolerated; occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.
• No significant toxicity has been documented up to high doses in animal studies[11][12].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on BPC-157 + TB-500?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
